Fuse Diagnostics is a company specializing in the development of innovative, rapid, low-cost diagnostic tests that bridge the gap between laboratory-based and point-of-need testing.

Fuse develops and manufactures innovative diagnostic products for a range of industries delivering lab quality information wherever it is needed through ultra-rapid, low-cost tests.

The immunoassay and PCR technologies that dominate the diagnostics industry have consistently failed to deliver lab-quality tests that are suitable for widespread decentralised use.  Using an all-new multianalytic chemistry and breakthrough product innovations Fuse has overcome the cost and performance challenges of established approaches to make accurate, point-of-need testing a reality for all.

Fuse Diagnostics

Following hot on the heels of our £1.6m seed round we are pleased to further announce a $1m Carb-X backed programme using our technology platforms to develop a CT/NG test to help in the fight against antimicrobial resistance. 💥 🎉 

https://fuse-dx.com/news

CARB-X will award US$1 million to Fuse Diagnostics to demonstrate proof-of-concept and feasibility ahead of the development of a rapid, instrument-free diagnostic for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). 
 
Gonorrhea, caused by Neisseria gonorrhoeae, is the second-most reported bacterial sexually transmitted infection, infecting approximately 82 million people globally in 2020. Patients with gonorrhea may experience serious health effects, including pelvic inflammatory disease, chronic pain, and infertility. Untreated gonorrhea can spread to the blood stream, which can be life threatening, and increase the risk of HIV infection. 
 
The award will fund the demonstration of performance of Fuse's CT/NG test, Apex, on clinical samples. Apex CT/NG utilizes innovative device designs and molecular technologies with the potential to deliver accuracy that is equivalent to lab-based PCR systems in an ultra-rapid, low-cost format ideally suited to flexible global deployment, including areas with remote access to secondary healthcare in low- and middle-income countries (LMICs). 
 
🔗 Read more: bit.ly/3VmwmXp 

#AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #Innovation #Biotechnology #LMICs #antibiotics 

Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) HHS Administration for Strategic Preparedness and Response National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Government of Canada Novo Nordisk Foundation Centre for Cellular and Molecular Platforms (C-CAMP) FIND German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE)

COM:FUSE-DX

Fuse Diagnostics

Analysis Not Available